By Dr. Peter Vanderklish Many neurological disorders appear very different clinically, yet an important biological theme is emerging across them: early loss of synaptic connectivity. In a recent article published in The Scientist, Dr. Vanderklish, Chief Science Officer at Spinogenix, examines synapse loss as a point of convergence across conditions including Alzheimer’s disease, amyotrophic lateral…
On September 24, 2025, Harmony announced that Zygel, a synthetic cannabidiol, missed the primary endpoint in its pivotal Fragile X trial. While the outcome was disappointing for many families in the Fragile X syndrome (FXS) community, it advanced understanding of the condition and reinforced the importance of early, quantitative clinical studies. In this discussion, Spinogenix…
When Stead Impact Ventures Board Chair Jerre Stead sat down with Dr. Stella Sarraf, founder and CEO of Spinogenix, their discussion centered on one shared belief: patients deserve more than incremental progress. They deserve treatments that can truly change their lives. For Stella, that mission is deeply personal. As a daughter and caregiver, she’s seen…
Posted in Life Science Podcast By: Ayesha Rashid, PhD In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Stella Sarraf, PhD, CEO and Founder of Spinogenix, a company pioneering novel neurodegenerative therapeutics designed to restore synapses with the potential to reverse cognitive and motor decline in conditions such as ALS, Alzheimer’s disease,…
Spinogenix announced results from its Phase 2 study of SPG601, showing a strong efficacy signal in improving abnormal brain activity in Fragile X syndrome (FXS). Presented at the NIH Fragile X Centers of Excellence Conference, the study demonstrated that SPG601 significantly reduced high-frequency gamma band activity, a key marker of brain dysfunction in FXS. Dr.…
July is Fragile X Awareness Month. We take this timely opportunity to hear our Chief Medical Advisor and Director of the Cincinnati Fragile X Research and Treatment Center, Dr. Craig Erickson, describe how SPG601- our novel approach to addressing synaptic deficits in Fragile X – can be of potential benefit to patients with Fragile X…